Furthermore, the presence of anti-CNS mimic antibodies—including those directed against anoctamin 2 (ANO2), alpha B crystallin (CRYAB), or GlialCAM—was associated with increased MS risk, albeit with highly variable effect sizes between studies [85,86]. Here, ANO2 is linked to myeloid sarcoma.